GettyImages-932533514-hero

Cancer Center

Selected Prostate Cancer Center of Excellence Research Publications, 2014-2019

Gritz ER, Arnold KB, Moinpour CM, Burton-Chase AM, Tangen CM, Probstfield JF, See WA, Lieber MM, Caggiano V, Moody-Thomas S, Szczepanek C, Ryan A, Carlin S, Hill S, Goodman PJ, Padberg RM, Minasian LM, Meyskens FL, Thompson IM Jr. Factors associated with adherence to an end-of-study biopsy: lessons from the prostate cancer prevention trial (SWOG-Coordinated Intergroup Study S9217). Cancer Epidemiol Biomarkers Prev 23(8):1638-48, 2014. (PMCID: PMC4119542) (PMID: 25028457)

 

Huang X, Yuan T, Liang M, Du M, Xia S, Dittmar R, Wang D, See W, Costello BA, Quevedo F, Tan W, Nandy D, Bevan GH, Longenbach S, Sun Z, Lu Y, Wang T, Thibodeau SN, Boardman L, Kohli M, Wang L. Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer. Eur Urol 67(1):33-41, 2014. (PMCID: PMC4252606) (PMID: 25129854)

 

Du M, Yuan T, Schilter KF, Dittmar RL, Mackinnon A, Huang X, Tschannen M, Worthey E, Jacob H, Xia S, Gao J, Tillmans L, Lu Y, Liu P, Thibodeau SN, Wang L. prostate cancer risk locus at 8q24 as a regulatory hub by physical interactions with multiple genomic loci across the genome. Hum Mol Genet 24(1):154-66, 2014. (PMCID: PMC4262497) (PMID: 25149474)

 

Pisansky TM, Hunt D, Gomella LG, Amin MB, Balogh AG, Chinn DM, Seider MJ, Duclos M, Rosenthal SA, Bauman GS, Gore EM, Rotman MZ, Lukka HR, Shipley WU, Dignam JJ, Sandler HM. Duration of androgen suppression before radiotherapy for localized prostate cancer: radiation therapy oncology group randomized clinical trial 9910. J Clin Oncol 33(4):332-9, 2014. (PMCID: PMC4302214) (PMID: 25534388)

 

Patch SK, Hull D, Thomas M, Griep SK, Jacobsohn K, See WA. Thermoacoustic contrast of prostate cancer due to heating by very high frequency irradiation. Phys Med Biol 60(2):689-708, 2015. (PMCID: PMC4292912) (PMID: 25554968)

 

Xia S, Kohli M, Du M, Dittmar RL, Lee A, Nandy D, Yuan T, Guo Y, Wang Y, Tschannen MR, Worthey E, Jacob H, See W, Kilari D, Wang X, Hovey RL, Huang CC, Wang L. Plasma genetic and genomic abnormalities predict treatment response and clinical outcome in advanced prostate cancer. Oncotarget 6(18):16411-21, 2015. (PMCID: PMC4599278) (PMID: 25915538)

 

Fahey JM, Girotti AW. Accelerated migration and invasion of prostate cancer cells after a photodynamic therapy-like challenge: Role of nitric oxide. Nitric Oxide 49:47-55, 2015. (PMCID: PMC4545398) (PMID: 26068242)

 

Krauss DJ, Hu C, Bahary JP, Souhami L, Gore EM, Chafe SM, Leibenhaut MH, Narayan S, Torres-Roca J, Michalski J, Zeitzer KL, Donavanik V, Sandler H, McGowan DG, Jones CU, Shipley WU. Importance of Local Control in Early-Stage prostate Cancer: Outcomes of Patients With Positive Post-Radiation Therapy Biopsy Results Treated in RTOG 9408. Int J Radiat Oncol Biol Phys 92(4):863-73, 2015. (PMCID: PMC4480595) (PMID: 26104939)

 

Voog JC, Paulus R, Shipley WU, Smith MR, McGowan DG, Jones CU, Bahary JP, Zeitzer KL, Souhami L, Leibenhaut MH, Rotman M, Husain SM, Gore E, Raben A, Chafe S, Sandler HM, Efstathiou JA. Cardiovascular Mortality Following Short-term Androgen Deprivation in Clinically Localized prostate Cancer: An Analysis of RTOG 94-08. Eur Urol 69(2):204-10, 2015. (PMCID: PMC4784682) (PMID: 26362090)

 

Thibodeau SN, French AJ, McDonnell SK, Cheville J, Middha S, Tillmans L, Riska S, Baheti S, Larson MC, Fogarty Z, Zhang Y, Larson N, Nair A, O'Brien D, Wang L, Schaid DJ. Identification of candidate genes for prostate cancer-risk SNPs utilizing a normal prostate tissue eQTL data set. Nat Commun 6:8653, 2015. (PMCID: PMC4663677) (PMID: 26611117)

 

Patch SK, Hull D, See WA, Hanson GW. Toward Quantitative Whole Organ Thermoacoustics With a Clinical Array Plus One Very Low-Frequency Channel Applied to prostate Cancer Imaging. IEEE Trans Ultrason Ferroelectr Freq Control 63(2):245-55, 2016. (PMCID: PMC4786189) (PMID: 26731749)

 

Du M, Tillmans L, Gao J, Gao P, Yuan T, Dittmar RL, Song W, Yang Y, Sahr N, Wang T, Wei GH, Thibodeau SN, Wang L. Chromatin interactions and candidate genes at ten prostate cancer risk loci. Sci Rep 6:23202, 2016. (PMCID: PMC4793270) (PMID: 26979803)

 

Xia Y, Huang CC, Dittmar R, Du M, Wang Y, Liu H, Shenoy N, Wang L, Kohli M. Copy number variations in urine cell free DNA as biomarkers in advanced prostate cancer. Oncotarget 7(24):35818-35831, 2016. (PMCID: PMC5094965) (PMID: 27127882)

 

Mak RH, Hunt D, Efstathiou JA, Heney NM, Jones CU, Lukka HR, Bahary JP, Patel M, Balogh A, Nabid A, Leibenhaut MH, Hamstra DA, Roof KS, Jeffrey Lee R, Gore EM, Sandler HM, Shipley WU. Acute and late urinary toxicity following radiation in men with an intact prostate gland or after a radical prostatectomy: A secondary analysis of RTOG 94-08 and 96-01. Urol Oncol 34(10):430.e1-7, 2016. (PMCID: PMC5035191) (PMID: 27381895)

 

Wang Y, Lieberman R, Pan J, Zhang Q, Du M, Zhang P, Nevalainen M, Kohli M, Shenoy NK, Meng H, You M, Wang L. miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1. Mol Cancer 15(1):70, 2016. (PMCID: PMC5105253) (PMID: 27832783)

 

Sreenath TL, Macalindong SS, Mikhalkevich N, Sharad S, Mohamed A, Young D, Borbiev T, Xavier C, Gupta R, Jamal M, Babcock K, Tan SH, Nevalainen MT, Dobi A, Petrovics G, Sesterhenn IA, Rosner IL, Bieberich CJ, Nelson P, Vasioukhin V, Srivastava S. ETS Related Gene mediated Androgen Receptor Aggregation and Endoplasmic Reticulum Stress in prostate Cancer Development. Sci Rep 7(1):1109, 2017. (PMCID: PMC5430720) (PMID: 28439080)

 

Ronen S, Abbott DW, Kravtsov O, Abdelkader A, Xu Y, Banerjee A, Iczkowski KA. PTEN loss and p27 loss differ among morphologic patterns of prostate cancer, including cribriform. Hum Pathol 65:85-91, 2017. (PMID: 28504208)

 

Hurrell SL, McGarry SD, Kaczmarowski A, Iczkowski KA, Jacobsohn K, Hohenwalter MD, Hall WA, See WA, Banerjee A, Charles DK, Nevalainen MT, Mackinnon AC, LaViolette PS. Optimized -value selection for the discrimination of prostate cancer grades, including the cribriform pattern, using diffusion weighted imaging. J Med Imaging (Bellingham) 5(1):011004, 2017. (PMCID: PMC5658575) (PMID: 29098169)

 

Larson NB, McDonnell SK, Fogarty Z, Larson MC, Cheville J, Riska S, Baheti S, Weber AM, Nair AA, Wang L, O'Brien D, Davila J, Schaid DJ, Thibodeau SN. Network-directed cis-mediator analysis of normal prostate tissue expression profiles reveals downstream regulatory associations of prostate cancer susceptibility loci. Oncotarget 8(49):85896-85908, 2017. (PMCID: PMC5689655) (PMID: 29156765)

 

Nichols RC, Hu C, Bahary JP, Zeitzer KL, Souhami L, Leibenhaut MH, Rotman M, Gore EM, Balogh AG, McGowan D, Michalski J, Raben A, Rudoler S, Jones CU, Sandler H. Serum testosterone changes in patients treated with radiation therapy alone for prostate cancer on NRG oncology RTOG 9408. Adv Radiat Oncol 2(4):608-614, 2017. (PMCID: PMC5707413) (PMID: 29204528)

 

Maranto C, Udhane V, Hoang DT, Gu L, Alexeev V, Malas K, Cardenas K, Brody JR, Rodeck U, Bergom C, Iczkowski KA, Jacobsohn K, See W, Schmitt SM, Nevalainen MT. STAT5A/B Blockade Sensitizes prostate Cancer to Radiation through Inhibition of RAD51 and DNA Repair. Clin Cancer Res 24(8):1917-1931, 2018. (PMCID: PMC6036914) (PMID: 29483142)

 

Zhang P, Xia JH, Zhu J, Gao P, Tian YJ, Du M, Guo YC, Suleman S, Zhang Q, Kohli M, Tillmans LS, Thibodeau SN, French AJ, Cerhan JR, Wang LD, Wei GH, Wang L. High-throughput screening of prostate cancer risk loci by single nucleotide polymorphisms sequencing. Nat Commun 9(1):2022, 2018. (PMCID: PMC5964124) (PMID: 29789573)

 

Kohli M, Li J, Du M, Hillman DW, Dehm SM, Tan W, Carlson R, Campion MB, Wang L, Wang L, Zhang H, Zhang P, Kilari D, Huang CC, Wang L. Prognostic association of plasma cell-free DNA-based androgen receptor amplification and circulating tumor cells in pre-chemotherapy metastatic castration-resistant prostate cancer patients. prostate Cancer Prostatic Dis 21(3):411-418, 2018. (PMCID: PMC6126974) (PMID: 29858592)

 

McGarry SD, Hurrell SL, Iczkowski KA, Hall W, Kaczmarowski AL, Banerjee A, Keuter T, Jacobsohn K, Bukowy JD, Nevalainen MT, Hohenwalter MD, See WA, LaViolette PS. Radio-pathomic Maps of Epithelium and Lumen Density Predict the Location of High-Grade prostate Cancer. Int J Radiat Oncol Biol Phys 101(5):1179-1187, 2018. (PMCID: PMC6190585) (PMID: 29908785)

 

Gao P, Xia JH, Sipeky C, Dong XM, Zhang Q, Yang Y, Zhang P, Cruz SP, Zhang K, Zhu J, Lee HM, Suleman S, Giannareas N, Liu S, PRACTICAL Consortium, Tammela TLJ, Auvinen A, Wang X, Huang Q, Wang L, Manninen A, Vaarala MH, Wang L, Schleutker J, Wei GH. Biology and Clinical Implications of the 19q13 Aggressive prostate Cancer Susceptibility Locus. Cell 174(3):576-589.e18, 2018. (PMCID: PMC6091222) (PMID: 30033361)

 

Sipeky C, Gao P, Zhang Q, Wang L, Ettala O, Talala KM, Tammela TLJ, Auvinen A, Wiklund F, Wei GH, Schleutker J. Synergistic Interaction of and Predisposes to Aggressive prostate Cancer. Clin Cancer Res 24(24):6265-6276, 2018. (PMID: 30181389)

 

Roach M, Moughan J, Lawton CAF, Dicker AP, Zeitzer KL, Gore EM, Kwok Y, Seider MJ, Hsu IC, Hartford AC, Horwitz EM, Yamoah K, Jones CU, Michalski JM, Lee WR, Pisansky TM, Rabinovitch R, Rotman M, Pryzant RM, Kim HE, Thomas CR Jr, Shipley WU, Sandler HM. Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial. Lancet Oncol 19(11):1504-1515, 2018. (PMCID: PMC6540797) (PMID: 30316827)

 

Reeve BB, Wang M, Weinfurt K, Flynn KE, Usinger DS, Chen RC. Psychometric Evaluation of PROMIS Sexual Function and Satisfaction Measures in a Longitudinal Population-Based Cohort of Men With Localized prostate Cancer. J Sex Med 15(12):1792-1810, 2018. (PMCID: PMC6294460) (PMID: 30539735)

 

Bruner DW, Pugh SL, Lee WR, Dignam JJ, Low D, Swanson GP, Shah AB, Malone S, Michalski JM, Dayes IS, Seaward SA, Nguyen PL, Hall WA, Pisansky TM, Chen Y, Sandler HM, Movsas B. Quality of Life in Patients With Low-Risk prostate Cancer Treated With Hypofractionated vs Conventional Radiotherapy: A Phase 3 Randomized Clinical Trial. JAMA Oncol Ahead of Print, 2019. (PMCID: PMC6459051) (PMID: 30763425)

 

McGarry SD, Bukowy JD, Iczkowski KA, Unteriner JG, Duvnjak P, Lowman AK, Jacobsohn K, Hohenwalter M, Griffin MO, Barrington AW, Foss HE, Keuter T, Hurrell SL, See WA, Nevalainen MT, Banerjee A, LaViolette PS. Gleason Probability Maps: A Radiomics Tool for Mapping prostate Cancer Likelihood in MRI Space. Tomography 5(1):127-134, 2019. (PMCID: PMC6403022) (PMID: 30854450)

 

Huang W, Chen Y, Fedorov A, Li X, Jajamovich GH, Malyarenko DI, Aryal MP, LaViolette PS, Oborski MJ, O'Sullivan F, Abramson RG, Jafari-Khouzani K, Afzal A, Tudorica A, Moloney B, Gupta SN, Besa C, Kalpathy-Cramer J, Mountz JM, Laymon CM, Muzi M, Kinahan PE, Schmainda K, Cao Y, Chenevert TL, Taouli B, Yankeelov TE, Fennessy F, Li X. The Impact of Arterial Input Function Determination Variations on prostate Dynamic Contrast-Enhanced Magnetic Resonance Imaging Pharmacokinetic Modeling: A Multicenter Data Analysis Challenge, Part II. Tomography 5(1):99-109, 2019. (PMCID: PMC6403046) (PMID: 30854447)

 

Thor M, Deasy JO, Paulus R, Robert Lee W, Amin MB, Bruner DW, Low DA, Shah AB, Malone SC, Michalski JM, Dayes IS, Seaward SA, Gore EM, Albert M, Pisansky TM, Faria SL, Chen Y, Koontz BF, Swanson GP, Pugh SL, Sandler HM. Tolerance doses for late adverse events after hypofractionated radiotherapy for prostate cancer on trial NRG Oncology/RTOG 0415. Radiother Oncol 135:19-24, 2019. (PMID: 31015166)